Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.62 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19438777 | 0.98 | SIGMAR1 (0.59) | SIGMAR1S1PR1S1PR3S1PR5CA12 | |
| SCHEMBL28968728 | 0.97 | SIGMAR1 (0.64) | SIGMAR1S1PR1S1PR3S1PR5CA12 | |
| Hydrochloric Acid SCHEMBL19438468 | 0.97 | SIGMAR1 (0.58) | SIGMAR1S1PR1S1PR3S1PR5CA12 | |
| SCHEMBL19438607 | 0.95 | SIGMAR1 (0.61) | SIGMAR1S1PR1S1PR3CA12CA7 | |
| SCHEMBL8829830 | 0.94 | SIGMAR1 (0.60) | SIGMAR1CA12CA7CA9CA14 | |
| SCHEMBL19438542 | 0.92 | SIGMAR1 (0.59) | SIGMAR1CA12CA7CA9CA14 | |
| SCHEMBL19438565 | 0.91 | SIGMAR1 (0.61) | SIGMAR1S1PR1S1PR3S1PR5CA12 | |
| SCHEMBL9404041 | 0.89 | MAPT (0.65) | CA12CA7CA9CA14 | |
| SCHEMBL20717644 | 0.89 | MAPT (0.65) | CA12CA7CA9CA14 | |
| SCHEMBL9219599 | 0.89 | MAPT (0.65) | CA12CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119200-A1 | TERTIARY AMIDES AND METHOD OF USE | ABBVIE PHARMACEUTICAL TRADING (SHANGHAI) CO., LTD. (CN) | 2019-04-25 | — | — | US | disclosed |
| WO-2017177004-A1 | TERTIARY AMIDES AND METHOD OF USE | ABBVIE INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20080070954-A1 | Acylurea Connected And Sulfonylurea Connected Hydroxamates | S*BIO PTE LTD. (SG) | 2008-03-20 | — | — | US | disclosed |
| US-20080070954-A1 | Acylurea Connected And Sulfonylurea Connected Hydroxamates | S*BIO PTE LTD. (SG) | 2008-03-20 | — | — | US | disclosed |
| US-20080070954-A1 | Acylurea Connected And Sulfonylurea Connected Hydroxamates | S*BIO PTE LTD. (SG) | 2008-03-20 | — | — | US | disclosed |
| EP-1685094-A4 | ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES | S BIO PTE LTD (SG) | 2007-08-22 | — | — | EP | disclosed |
| EP-1685094-A1 | ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES | S*Bio Pte Ltd (SG) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005040101-A1 | ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES | S*BIO PTE LTD (SG) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005040101-A1 | ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES | S*BIO PTE LTD (SG) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070954-A1 | Acylurea Connected And Sulfonylurea Connected Hydroxamates | HDAC1, HDAC3, HDAC4 | SIGMAR1 4320/4885S1PR1 3514/4885S1PR3 2817/4885 |
| US-20190119200-A1 | TERTIARY AMIDES AND METHOD OF USE | LPAR1, LPAR3, LPAR2 | SIGMAR1 233/4885S1PR1 25/4885S1PR3 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.